Evidence map›Paper›PMID 39769276›Full record

ReviewInternational journal of molecular sciences2024

Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development.

Nevena Todorovic, Serena Martinelli, Giulia Nannini, Ralf Weiskirchen, Amedeo Amedei

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Inflammatory factors collaboratively linkFrontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nevena TodorovicDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-9227-1067
Serena MartinelliDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-4992-2252
Giulia NanniniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Ralf WeiskirchenInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany.ORCID 0000-0003-3888-0931
Amedeo AmedeiDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-6797-9343

Funding

the European Union-NextGenerationEU-National Recovery and Resilience Plan, Mission 4 Component 2-Investment 1.5-THE-Tuscany Health Ecosystem-ECS00000017-CUP B83C22003920001; #NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research (M the European Union-NextGenerationEU-National Recovery and Resilience Plan, Mission 4 Component 2-Investment 1.5-THE-Tuscany Health Ecosystem-ECS00000017-CUP B83C22003920001; #NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research (M
6 · The paper itself

Abstract

Chronic liver disease is characterised by persistent inflammation, tissue damage, and regeneration, which leads to steatosis, fibrosis, and, lastly, cirrhosis and hepatocellular carcinoma (HCC). HCC, the most prevalent form of primary liver cancer, is one of the leading causes of cancer-related mortality worldwide. The gut microbiota plays a fundamental role in human physiology, and disturbances in its critical balance are widely recognised as contributors to various pathological conditions, including chronic liver diseases, both infectious and non-infectious in nature. Growing interest in microbiota research has recently shifted the focus towards the study of intratumoural microbiota, referred to as the "oncobiome", which can significantly impact the development and progression of HCC. In this review, we discuss existing research and provide an overview of the microbiota influence on viral hepatitis, particularly in shaping the progression of liver disease caused by the hepatitis B and hepatitis C viruses. We also explore microbial dysbiosis and its contribution to the silent and dangerous progression of non-alcoholic fatty liver disease. Additionally, we address the impact of alcohol on the liver and its interaction with the microbiota, tracing the pathway from inflammation to cirrhosis and cancer. The review emphasises the most common etiologies of hepatocellular carcinoma.

Indexed as

Carcinoma, HepatocellularDysbiosisGastrointestinal MicrobiomeLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseAnimalsHumanscirrhosisfibrosisgut microbiotahepatocellular carcinomaoncobiomesteatosis

Identifiers

PMID39769276
PMCPMC11677376

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.